- McKesson Corporation MCK reported fourth-quarter FY21 EPS of $5.05, which beat the analyst consensus estimate of $5.04 versus $4.27 a year ago.
- Sales increased 1% Y/Y to $59.14 billion, which missed the analyst consensus estimate of $61.09 billion.
- Revenue growth of 1% Y/Y was primarily due to market growth and higher volumes from retail national account customers in the U.S. Pharmaceutical segment.
- U.S. Pharmaceutical Segment revenues were $47.0 billion, an increase of 3% Y/Y, driven by market growth and higher volumes from retail national account customers, partially offset by the prior year’s acceleration in demand caused by the onset of the COVID-19 pandemic and branded to generic conversions.
- Prescription Technology Solutions Segment sales increased 7% to $789 million, led by higher volumes of technology and service offerings to support biopharma customers.
- Medical-Surgical Solutions sales improved 23% to $2.7 billion, driven by demand for COVID-19 tests.
- Adjusted gross profit was approximately flat to the prior year as inventory charges in the Medical-Surgical segment and the previously mentioned last year demand increase, driven by COVID, largely offset the contribution of COVID-19 vaccine distribution and kitting programs and the distribution of COVID-19 tests.
- Adjusted operating profit increased 12% to $1.16 billion.
- Despite the pandemic-driven uncertainty on FY22 financials, “we do expect a return to pre-COVID levels of prescription volumes and patient engagement levels in the second half of fiscal 2022,” CEO Brian Tyler said on the earnings call.
- McKesson guides FY22 adjusted EPS of $18.85 – 19.45, indicating 9.5% - 13% Y/Y growth. The consensus EPS stands at $18.85 per share.
- Guidance assumes $0.50 to $0.70 adjusted EPS related to the U.S. government’s COVID-19 vaccine distribution and kitting programs.
- McKesson sees FY22 revenue growth of 3% to 6%.
- Goldman Sachs maintains McKesson with a Buy and raises the price target from $231 to $257.
- Price Action: MCK shares are up 6.6% at $197.34 during market trading hours on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
